FCM
SRPT icon

Farallon Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Farallon Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-133,300
Closed -$21.1M – 176
2024
Q2 		$21.1M Buy
+133,300
New +$17.1M 0.09% 73
2020
Q1 		– Sell
-400,000
Closed -$51.6M – 116
2019
Q4 		$51.6M Buy
+400,000
New +$40.4M 0.35% 55

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Farallon Capital Management's SRPT Position: Q2 2025 in Review

Farallon Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 2,341,424 shares — an estimated $149M sold.

Farallon Capital Management first reported a position in SRPT in Q3 2018 and held it in 24 quarters. The position peaked at $363M in Q2 2024. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Farallon Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Farallon Capital Management sold 2,341,424 Sarepta Therapeutics shares in Q2 2025, an estimated $149M.
  • Farallon Capital Management first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 24 quarters.
  • Farallon Capital Management's Sarepta Therapeutics position peaked at $363M in Q2 2024.
  • 363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Farallon Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.